ClinicalTrials.gg
Not yet recruitingNCT06124703Updated Nov 13, 2023

Different Dosing Regimens of STOP-AST

An interventional study of Prednisone tablet and Ginkgo Biloba Extract in Hearing Loss, Tinnitus and Sensorineural Hearing Loss, sponsored by Eye & ENT Hospital of Fudan University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-11-13.

Primary conditionHearing Loss, SensorineuralRegistry: Hearing LossReclassifiedWhy we changed it
Registry
Hearing Loss — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hearing Loss, Sensorineural
Why
  1. The study's listed conditions name Hearing Loss, Sensorineural, a narrower term within Hearing Loss.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eye & ENT Hospital of Fudan University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn about the different dose regimens of the efficacy of oral steroids in the acute tinnitus population. Participants will receive different appropriate dosages of prednisone tablets and oral Ginkgo Biloba tablets.

Read the detailed description

The purpose of this clinical study was to investigate the efficacy and to compare two different oral doses of short-term systemic steroid therapy for acute tinnitus.

02

Conditions studied

  • Hearing Loss
  • Tinnitus
  • Sensorineural Hearing Loss

Browse trials for

03

In context

Hearing Loss, Sensorineural Reclassified

348 studies on the registry are indexed under Hearing Loss, Sensorineural; 103 are open to participants now.

This study's planned enrollment of 162 is above the median of 32 across 249 interventional studies indexed under Hearing Loss, Sensorineural.

Browse Hearing Loss, Sensorineural studies →

Lead sponsor

Eye & ENT Hospital of Fudan University is the lead sponsor of 127 studies on the registry; 71 are open to participants now.

Compared within Hearing Loss, Sensorineural, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hearing Loss. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-60 years old;
  2. primary complaint of subjective tinnitus ≤ 1 months of duration;
  3. a decline in auditory function by audiological assessments on the day of the test, of which the outcome must either satisfy one of the following conditions:

    1. a reduced distortion product otoacoustic emissions (DPOAE) amplitude in individuals with normal Pure tone audiometry (PTA) results;
    2. more than a PTA threshold > 20 dB with frequencies between 125 and 8000 Hz, but not exhibited idiopathic sudden sensorineural hearing loss;
  4. a state of good general condition;
  5. with good adherence to participation and signed .

Exclusion criteria

Exclusion Criteria:

  1. active middle ear pathology;
  2. patients who had received treatment for their current condition prior to the study;
  3. both the PTA and DPOAE with normal outcomes;
  4. hearing implants;
  5. history of known (including osteoporosis, peptic ulcers, poorly controlled hypertension, diabetes, chronic liver or renal insufficiency, tumorous condition, alcohol abuse, pregnant patients, and women on estrogen-containing oral steroids).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
162 participants (estimated)

Study arms

  • Active comparator
    dose-tapering regimen

    The dose selection of oral prednisone is the maximum daily dose for 4 days, followed by a taper every 2 days

    Drug: Prednisone tablet · Drug: Ginkgo Biloba Extract

  • Experimental
    no taper regimen

    The dose selection of oral prednisone is the maximum daily dose, applied for 5 consecutive days

    Drug: Prednisone tablet · Drug: Ginkgo Biloba Extract

Interventions

  • DrugPrednisoneStudies of PrednisonePrednisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Prednisone acetate tablet (5 mg prednisone acetate per tablet) was provided

    Also known as: Prednisone

  • Ginkgo biloba extract (EGb) is a compound drug derived from Ginkgo biloba trees native to China.

    Also known as: EGb

06

What researchers measure

Primary outcomes

  1. tinnitus handicap inventory (THI)

    The THI is a self-administered test, including 25 questions with grades four categories of tinnitus severity: slight corresponding to a score of 0-16, mild (18-36), moderate (38-56), severe (58-100). The higher the score the more severe the tinnitus

    Time frame: one week from baseline

  2. tinnitus handicap inventory (THI)

    The THI is a self-administered test, including 25 questions with grades four categories of tinnitus severity: slight corresponding to a score of 0-16, mild (18-36), moderate (38-56), severe (58-100). The higher the score the more severe the tinnitus

    Time frame: two weeks from baseline

  3. tinnitus handicap inventory (THI)

    The THI is a self-administered test, including 25 questions with grades four categories of tinnitus severity: slight corresponding to a score of 0-16, mild (18-36), moderate (38-56), severe (58-100). The higher the score the more severe the tinnitus

    Time frame: one month from baseline

Secondary outcomes

  1. visual analog scale (VAS)

    mark the severity of tinnitus on a horizontal scale from 0 to 10. The higher the score, the more severe the symptoms.

    Time frame: one week from baseline

  2. visual analog scale (VAS)

    mark the severity of tinnitus on a horizontal scale from 0 to 10. The higher the score, the more severe the symptoms.

    Time frame: two weeks from baseline

  3. visual analog scale (VAS)

    mark the severity of tinnitus on a horizontal scale from 0 to 10. The higher the score, the more severe the symptoms.

    Time frame: one month from baseline

  4. the Athens Insomnia Scale-8 (AIS-8)

    The AIS comprises eight items that commonly measure difficulties in falling asleep or maintaining sleep to quantify the presence of insomnia. The higher the AIS score, the lower the sleep quality and mental status. The AIS identifies three types of sleep disorders: no insomnia (score below 4), suspicious (4-6), and insomnia (score between 7-24).

    Time frame: one week from baseline

  5. the Athens Insomnia Scale-8 (AIS-8)

    The AIS comprises eight items that commonly measure difficulties in falling asleep or maintaining sleep to quantify the presence of insomnia. The higher the AIS score, the lower the sleep quality and mental status. The AIS identifies three types of sleep disorders: no insomnia (score below 4), suspicious (4-6), and insomnia (score between 7-24).

    Time frame: two weeks from baseline

  6. the Athens Insomnia Scale-8 (AIS-8)

    The AIS comprises eight items that commonly measure difficulties in falling asleep or maintaining sleep to quantify the presence of insomnia. The higher the AIS score, the lower the sleep quality and mental status. The AIS identifies three types of sleep disorders: no insomnia (score below 4), suspicious (4-6), and insomnia (score between 7-24).

    Time frame: one month from baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2023; primary completion for Feb 2024, 3 months later.

Of 82 non-industry interventional studies with no phase under Hearing Loss, Sensorineural, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 83. This study's planned 3 months is below that.

Counting every sponsor, half of 162 studies reached it within 22 months; a quarter within 6 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2023
First posted
Nov 9, 2023
StartEst.
Nov 10, 2023
Primary completionEst.
Feb 10, 2024
CompletionEst.
Nov 30, 2024
Last update
Nov 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06124703
Responsible party
Sponsor
First posted
Nov 9, 2023
Start date
Nov 10, 2023 (estimated)
Primary completion
Feb 10, 2024 (estimated)
Completion
Nov 30, 2024 (estimated)
Last update
Nov 13, 2023

Study contacts

Shan Sun
Contact
sunshine7896@126.com
+86-18917786102
Peifan Li
Contact
20211260020@fudan.edu.cn
+86-18373151369
Shan Sun
principal investigator · Eye and ENT Hospital of Fudan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prednisone

Start the discussion